Sonoma Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

7. Stock-Based Compensation (Tables)

7. Stock-Based Compensation (Tables)

3 Months Ended

Jun. 30, 2012

Employee Stock-Based Compensation Expense

Employee stock-based compensation expense is as follows (in thousands):

	Three Months Ended June 30,
	2012		2011
Cost of revenues	$	32	$	20
Research and development		67		62
Selling, general and administrative		209		473
Total stock-based compensation	$	308	$	555

Summary of All Option Activity

A summary of all option activity as of June 30, 2012 and changes during the three months then ended is presented below:

	Shares (in thousands)			Weighted- Average Exercise Price		Weighted- Average Contractual Term		Aggregate Intrinsic Value (in thousands)
Options
Outstanding at April 1, 2012		6,266		$	2.36
Granted		–			–
Exercised		–			–
Forfeited or expired		(61	)		5.76
Outstanding at June 30, 2012		6,205		$	2.32		7.26	$	160
Exercisable at June 30, 2012		4,920		$	2.48		6.90	$	158

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details